Clonidine Hydrochloride is a centrally acting alpha-2 adrenergic receptor agonist manufactured to stringent regulatory standards in the United States. This high-purity active pharmaceutical ingredient is classified as an API/pharmaceutical intermediate and typically meets USP specifications. Supplied in a sealed, industrial-grade 25 kg drum, this white to off-white crystalline powder is highly soluble in water and ethanol for pharmaceutical processing.
This versatile API exerts its pharmacological effects by stimulating alpha-2 adrenergic receptors in the central nervous system, which reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance, lowered blood pressure, and reduced heart rate. The API is a core component in the commercial manufacture of oral tablets and extended-release formulations primarily indicated for the treatment of hypertension. It is also widely incorporated into pharmaceutical products for the management of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric and adult populations, as a standard adjunct in supervised opioid withdrawal protocols for managing autonomic symptoms, and as an analgesic for certain neuropathic and chronic pain conditions.
Important Notice: Clonidine is not classified as a controlled substance under the U.S. Controlled Substances Act, as it has minimal potential for abuse compared to narcotics, stimulants, or benzodiazepines. However, as a potent prescription medication, it is strictly regulated and intended solely for industrial-scale pharmaceutical synthesis by licensed manufacturers. Purchasers should ensure full compliance with all federal, regional, and local drug and chemical distribution regulations governing prescription APIs. It is intended exclusively for registered pharmaceutical manufacturers, contract manufacturing organizations, and research institutions with appropriate licensing.











